OR WAIT null SECS
August 09, 2022
Amgen’s acquisition of Chemocentryx includes the autoimmune disease drug Tavneos (avacopan).
August 05, 2022
La Jolla’s acquisition of Carterra’s LSA Platform is designed to advance their immunological and infectious disease research.
August 03, 2022
Ipsen and Marengo Therapeutics will collaborate to advance two precision immuno-oncology candidates.
July 26, 2022
Discovery Life Sciences’ acquisition of AllCells is intended to bolster its cell and gene therapy products and services.
AstraZeneca's acquisition of TeneoTwo will give the company access to its clinical-stage T-cell engager, TNB-486, strengthening their hematological cancer pipeline.
July 25, 2022
Merck, known as MSD outside the United States and Canada, and Orion Corporation are collaborating to develop and commercialize a treatment for metastatic castration-resistant prostate cancer.
July 19, 2022
Cytiva has acquired a new chromatography resins manufacturing site in the United States as part of its $1.5 billion capacity expansion investment.
July 18, 2022
Royalty Pharma is paying $1.6 billion for the royalty rights to Trelegy Ellipta, a treatment for COPD and asthma.
Vertex’s $320 million acquisition of ViaCyte will give the company complementary capabilities for its Type 1 diabetes therapy program.
July 13, 2022
Merck, known as MSD outside the United States and Canada, now offers the Merck Digital Sciences Studio, designed to enable innovative tech for drug discovery and development.